SAHPRA Approves Pfizer’s Paxlovid COVID-19 Treatment
SAHPRA announced the registration of Paxlovid COVID-19 treatment, an anti-viral medicine manufactured by Pfizer, to treat COVID-19. This is a 5-day oral treatment for mild to moderate COVID-19 in adults who do not require supplemental oxygen and who are at increased risk for progression to severe COVID-19.
International sources provide guidelines regarding prescribing in liver and kidney disease as well as possible drug interactions including statin therapy, anticoagulation and some hormonal birth control treatments.
Recent Posts
Cost-Effectiveness of T1D Screening Effectiveness in Canadian Children
T1D screening effectiveness in the general population substantially outperforms targeted approaches based on family history or genetic risk, according to a new Canadian health economic analysis. General population autoantibody screening detects far more at-risk children than family-history or gen...
Novartis Acquires Mutant-Selective PI3Kα Inhibitor to Enhance Breast Cancer Treatment Options
Novartis has agreed to acquire SNV4818, a pan-mutant-selective PI3Kα inhibitor from Synnovation Therapeutics, targeting PIK3CA mutations...
Semaglutide India Partnership: Enhancing Access to Diabetes Treatment
The Semaglutide India partnership between Lupin Limited and Zydus Lifesciences Limited formalizes a licensing and supply agreement to co-market an innovative Semaglutide Injection (15 mg/3 ml) with a patient-friendly reusable pen device in the Indian market. This collaboration leverages Lupin's e...